<DOC>
	<DOCNO>NCT00529243</DOCNO>
	<brief_summary>The primary objective study : To assess virologic effect change enfuvirtide MK-0518 ( raltegravir ) human immunodeficiency virus type 1 ( HIV-1 ) infect patient undetectable level serum human immunodeficiency virus ( HIV ) ( &lt; 75 copies/ml branch deoxyribonucleic acid ( bDNA ) assay , &lt; 50 copies/ml Ultrasensitive Polymerase Chain Reaction ( PCR ) assay ) current HIV medication regimen . Hypothesis : HIV-1 infected individual well control enfuvirtide contain regimen HIV RNA level limit quantification safely investigational integrase inhibitor , MK-0518 substitute enfuvirtide without loss virologic suppression .</brief_summary>
	<brief_title>Evaluating Effect CHanging EnfuvirtidE Raltegravir HIV Infected Subjects</brief_title>
	<detailed_description>Human immunodeficiency virus type 1 ( HIV-1 ) infect patient undetectable viral load enfuvirtide contain regimen Kaiser Permanente Hayward , Los Angeles , San Francisco , Santa Clara Medical Centers enrol . Patients receive open label MK-0518 ( raltegravir ) 400mg orally twice day substitution enfuvirtide 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible participation study . 1 . Subject ≥ 18 year age able understand willing sign write informed consent form , must obtain prior initiation study . 2 . Documented laboratory diagnosis HIV1 infection ( positive Enzymelinked immunosorbent assay ( ELISA ) HIV1 antibody test confirm western blot , p24 assay , HIV1 RNA , culture ) . 3 . Have document plasma HIV1 RNA level ( ) &lt; 75 copies/ml branch deoxyribonucleic acid ( bDNA ) assay , &lt; 50 copies/ml Ultrasensitive Polymerase Chain Reaction ( PCR ) least 6 month prior screen visit . 4 . Currently receive stable antiretroviral regimen consist enfuvirtide plus least 2 antiretrovirals least 6 month . 5 . Negative serum pregnancy test ( female childbearing potential ) willing use adequate method contraception throughout duration study . Patients meet follow exclusion criterion enrol study . 1 . Any prior therapy MK0518 HIV1 integrase inhibitor . 2 . Any HIV1 viral load &gt; 75 copies/ml bDNA assay , &gt; 50 copies/ml Ultrasensitive PCR assay 6 month prior screen visit ( A single `` blip '' HIV1 viral load &gt; 75 copy &lt; 400 copy bDNA assay , &gt; 50 copy &lt; 400 copy Ultrasensitive PCR assay six month prior screen visit least one subsequent HIV1 viral load limit detection accept . ) 3 . Any previous know hypersensitivity component study drug formulation . 4 . Weight &lt; 40 kilogram . 5 . Patient require anticipated require prohibit medication note protocol . 6 . Acute therapy serious illness ( opinion investigator ) within 14 day prior study entry unless subject complete ≥ 7 day therapy consider clinically stable investigator . 7 . Any condition , opinion investigator , would compromise subject 's ability participate study . 8 . Any active opportunistic infection Centers Disease Control Prevention ( CDC ) Category C condition ( exception stable cutaneous Kaposi 's Sarcoma waste syndrome due HIV infection ) . 9 . Any malignancy require chemotherapy . 10 . Subject follow laboratory result screen : Hemoglobin &lt; 8.0 gr/dl Absolute neutrophil count &lt; 750 cells/ml Platelet count &lt; 40,000 Creatinine &gt; 2.0 calculate creatinine clearance &lt; 40 ml/min 11 . Female patient pregnant breastfeeding , expect conceive donate egg study . Male patient plan impregnate provide sperm donation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Treatment Experience</keyword>
	<keyword>On enfuvirtide</keyword>
</DOC>